Top 7 China Gene Therapy Companies 2025
China's gene therapy market surpassed RMB 15 billion in 2025, with 5 gene therapy products approved and 300+ clinical trials ongoing across AAV gene therapy, CAR-T cell therapy, gene editing, and mRNA therapeutics. China has become the world's second-largest gene therapy R&D hub after the US, with significant cost advantages in manufacturing and clinical development. Chinese companies are advancing both domestic approvals and global partnerships.
TL;DR: China's gene therapy market exceeds RMB 15B with 5 approved products and 300+ trials. Frontera Therapeutics leads in AAV ophthalmic gene therapy while Juventas Cell Therapy operates the largest CAR-T manufacturing facility in Asia.
Top Companies
Frontera Therapeutics ( Frontiera Therapeutics / frontier)
AAV ophthalmic gene therapy leaderFrontera Therapeutics develops AAV-based gene therapies for inherited retinal diseases. Its lead program for choroideremia has received both US and Chinese regulatory fast-track designations. It operates a GMP-grade AAV manufacturing facility in Suzhou with 200L bioreactor capacity.
Juventas Cell Therapy (亘喜生物)
Largest CAR-T facility in AsiaJuventas Cell Therapy operates Asia's largest CAR-T manufacturing facility with 500L bioreactor capacity, producing allogeneic and autologous CAR-T cell therapies. Its GC007F for B-cell acute lymphoblastic leukemia has shown 95%+ complete remission rates in clinical trials.
Legend Biotech (传奇生物)
Global CAR-T commercial successLegend Biotech's Carvykti (cilta-cel) is a globally approved BCMA-targeted CAR-T therapy for multiple myeloma, generating USD 1B+ in annual revenue through its partnership with Janssen. It represents the most commercially successful cell therapy developed by a Chinese company, manufactured at facilities in Nanjing and New Jersey.
Bioray Laboratories (必锐生物)
AAV gene therapy platformBioray develops AAV-based gene therapies for rare diseases and neurological conditions. Its proprietary AAV capsid engineering platform enables tissue-specific gene delivery with improved transduction efficiency. It has multiple programs in Phase I/II clinical trials for inherited metabolic disorders.
Beacon Therapeutics (星眸生物)
Gene therapy for eye diseasesBeacon Therapeutics focuses on gene therapies for inherited retinal dystrophies and age-related macular degeneration. Its AAV-based gene replacement therapy for Leber congenital amaurosis has reached Phase II/III trials with promising visual acuity improvements.
EdiGene (博雅辑因)
CRISPR gene editing leaderEdiGene is China's leading CRISPR gene editing company, developing ex vivo gene editing therapies for blood disorders and in vivo gene editing for metabolic diseases. Its lead program for transfusion-dependent beta-thalassemia has received IND approval and entered Phase I clinical trials in China.
Stemirna Therapeutics (斯微生物)
mRNA therapy pioneerStemirna is one of China's earliest mRNA therapeutic companies, developing mRNA vaccines and therapeutics using lipid nanoparticle delivery. Its pipeline includes mRNA cancer vaccines, protein replacement therapies, and infectious disease vaccines, with manufacturing facilities in Shanghai and Zhejiang.
Comparison Table
| Company | Technology | Therapeutic Area | Clinical Stage | Key Achievement |
|---|---|---|---|---|
| Frontera Therapeutics | AAV gene therapy | Ophthalmic | Phase I/II | Fast-track designations |
| Juventas Cell Therapy | CAR-T cell therapy | Hematology | Phase II | 95%+ CR rate |
| Legend Biotech | CAR-T (cilta-cel) | Multiple myeloma | Approved | USD 1B+ revenue |
| Bioray Labs | AAV capsid engineering | Rare diseases | Phase I/II | Novel capsids |
| Beacon Therapeutics | AAV gene therapy | Eye diseases | Phase II/III | Visual improvement |
| EdiGene | CRISPR editing | Blood disorders | Phase I | IND approved |
| Stemirna | mRNA + LNP | Cancer, vaccines | Phase I | mRNA pipeline |
Frequently Asked Questions
How many gene therapy products are approved in China?
China has approved 5 gene/cell therapy products: Carteyva (Juventas, CAR-T for ALL), Fucaso (Juventas, CAR-T for lymphoma), Carvykti (Legend Biotech/Janssen, CAR-T for myeloma), Yikaida (Fosun Kite, CAR-T for lymphoma), and Nakexa (IASO Bio, CAR-T for myeloma). All approved products are CAR-T therapies for hematological cancers.
How does China's gene therapy R&D compare globally?
China is the world's second-largest gene therapy R&D hub with 300+ clinical trials, after the US (500+ trials). China has particular strengths in CAR-T cell therapy (50+ trials) and AAV gene therapy. Chinese companies offer 60-70% lower clinical trial costs, attracting global pharma partnerships for development and manufacturing.
What are China's gene therapy pricing and access challenges?
Gene therapies in China are priced significantly lower than in the US: CAR-T therapies cost RMB 800K-1.2M (vs USD 400-500K in US), and AAV gene therapies are expected at RMB 2-5M per treatment. Access remains limited due to cost, but commercial health insurance pilots and government rare disease programs are improving affordability.
Which Chinese companies are developing CRISPR therapies?
EdiGene leads China's CRISPR therapeutic development, focusing on ex vivo editing for beta-thalassemia and sickle cell disease. Other CRISPR companies include Qihan Biotech (in vivo editing for metabolic diseases) and GenScript's therapeutic division. China's gene editing therapies are 2-3 years behind US leaders (Vertex/CRISPR Therapeutics).
What is the manufacturing advantage of Chinese gene therapy companies?
Chinese companies offer 50-70% lower manufacturing costs for viral vectors (AAV, lentivirus) and cell therapy products, driven by lower labor costs, government-subsidized facilities, and growing CDMO capabilities (Wuxi Advanced Therapies, Bioray). This cost advantage is attracting global pharma outsourcing to China.